Loading patent…
AssigneeVertex Pharmaceuticals Incorporated
InventorsGrant E. Blouse, Brajesh Kumar, Tom Knudsen, Jan Kristian Jensen, Emil Oldenburg, Christine René Schar, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way, Agnieszka Jendroszek, Arzu Sandikci, Jim McGuire, Shyam Rajan Iyer, Natacha Le Moan
Estimating the term…
Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.
A fusion construct comprising a first component and a second component, wherein the first component comprises a wild type complement factor I (CFI), wherein the second component comprises a half-life extender, wherein the second component is fused to the N-terminal end of the first component, and wherein the fusion construct has a cleavage activity for C3b and/or C4b that is substantially equivalent to a plasma-derived CFI.
Dependencies are inferred from the claim text.